Savara has multiple products in various stages of clinical development.


  • Savara expects to start enrollment of patients in a pivotal phase III clinical trial of AeroVanc in cystic fibrosis patients with chronic MRSA infection in the U.S. and Canada in Q1 of 2017. See AeroVanc.com for more details.
  • A phase II/III clinical trial of Molgradex to treat patients with PAP is on-going in the EU and Japan.
  • FVIIa is currently in non-clinical development and anticipates initiating clinical studies in 2018.

Go to products

Back to Top